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Abstract
Objective: The combination of surgery and chemotherapy improves the prognosis of patients with osteogenic sarcoma of the limbs
without detectable metastases at presentation. However, lung metastases are a frequent complication. To evaluate the role of the resection of
pulmonary metastases of osteogenic sarcoma of the limbs, we have reviewed our experience with this type of surgery, combined with a
multidrug chemotherapy protocol. Patients and methods: From January 89 to December 97, 198 patients operated on for osteogenic
sarcomas of the limbs were followed in our centre. Of these, 31 patients (15.7%), with a mean age of 25 years (range 10±54 years),
developed lung metastases and had undergone 45 thoracotomies. All patients received chemotherapy, followed by resection of metastatic
lesions and additional chemotherapy. The mean time interval between resection of the primary tumour and the diagnosis of lung metastases
was 22 months (4±122 months). Eight patients (25.8%) needed more than one (2±4) thoracotomy. The mean time interval between the ®rst
and second thoracic surgeries was 9.2 months (2±14 months). Results: There was no operative mortality or major morbidity. During the 45
thoracotomies, ®ve lobectomies and 40 wedge resections were necessary. The mean number of metastases resected per thoracotomy was 3.4
(range 1±10). The degree of necrosis was evaluated by seriated sections for a histologic study. In the end the mean necrotic volume was
calculated. A strong correlation was found between the degree of necrosis of the metastases and the need for reoperation for new metastatic
lesions, because all the patients who needed more than one operation had less than 80% of necrosis of metastases. The patients were followed
for a mean period of 28 months (6±72 months). Ten patients (32.2%) died of related causes at a mean of 19.4 months after thoracic surgery,
three of whom had more than one operation. The 3-year survival after metastasectomy was 61%. Patients without pulmonary metastases had
a 3-year survival of 79%. Conclusions: In patients with lung metastases of an osteogenic sarcoma, the combination of chemotherapy and
surgery improves the outcome. In our series the mortality was not in¯uenced by the number or thoracotomies required. q 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
The lung is the most common site of metastisation of
malignant tumours with the exception of those occurring
in organs that drain to the portal venous system [1]. Pulmon-
ary metastases occur in approximately 30% of all malignant
tumours and in up to 60% of patients with sarcoma of the
limbs treated surgically. The development of pulmonary
metastases is a factor of very poor prognosis, the majority
of untreated patients dying within 6 months of diagnosis.
The role of surgery in the treatment of pulmonary metas-
tases has evolved with time, also in¯uenced by advances in
the knowledge of tumoural biology and by better under-
standing of the natural history of malignant tumours.
Early resection of pulmonary metastases improves survival
markedly [2±5]. The 5-year survival may reach 50%,
although true cure is extremely rare, the majority of patients
eventually dying of the disease.
Multiple metastases, unilateral or bilateral, and further
metastisation are frequent, obliging to multiple resection,
bilateral approach and repeated thoracotomies [6].
However, the number of metastases, bilaterality and further
surgery do not appear to in¯uence survival signi®cantly.
Currently, the number of metastases that can be resected
is only limited by the capacity to eliminate all the metastatic
disease, but leaving enough pulmonary parenchyma to guar-
antee a reasonable functional respiratory capacity.
Chemotherapy appears to further improve prognosis by
its effect on micrometastases [7]. The association of multi-
agent chemotherapy and of surgery of both primary and
secondary tumours has improved the 3-year survival up to
70%.
We have reviewed our recent experience in the treatment
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of patients who developed pulmonary metastases after
surgical treatment of osteogenic sarcoma of the limbs.
2. Patients and methods
2.1. Patients
In the 9-year period from January 1989 to December
1997, 198 patients with osteogenic sarcoma of the limbs
were operated on in our hospital. Of this group, 31 patients
(15.7%), with a mean age of 25 years (range 10±54 years),
developed pulmonary metastases. There were 21 males and
10 females, and nine patients (29.0%) were under 15 years
of age at the time of the initial operation. The primary
tumour had been located in the femur in 11 patients
(35.5%), in the tibia in 10 (32.3%), in the humerus in four
(12.9%) and in other sites in six (19.4%). Following the
excision of the primary tumour, all patients had CT scans
every 3±6 months until 2 years free of disease had elapsed.
A complete clinical, laboratorial and imagiologic workout
was undertaken to identify or exclude the presence of metas-
tases in other organs and systems. Magnetic resonance
imaging was performed in some patients but none had
high resolution spiral thoracic CT because it is not available
to us. All 31 patients were evaluated by CT scan before
thoracic exploration, in order to determine the number and
localisation of metastases present in each lung. No comment
on speci®city can be made, however, as speci®c roentgeno-
graphic abnormalities were not correlated with individually
resected metastases.
Patients were selected for resection of pulmonary metas-
tases if they met the following criteria: (1) primary tumour
completely eradicated and without local recurrence; (2) no
recognisable metastases in other organs besides the lung;
and (3) all pulmonary metastases resectable with a low
operative risk and an adequate residual pulmonary function.
Factors such as the number of metastases, unilateral versus
bilateral involvement, disease-free interval and duplication
time of the osteogenic sarcoma were not factors of exclu-
sion. There were another 27 patients (14%) who developed
lung metastases but were not included in this group because
they did not meet these criteria.
2.2. Chemotherapy
The therapeutic control for patients with lung metastases
of osteogenic sarcoma was based on the combination of
chemotherapy and surgery, as indicated in Fig. 1. This
was initiated by three cycles of pre-operative chemotherapy
with methotrexate (MTX) 12 g/m2, adriamycin (ADR) 90
mg/m2, cisplatinium (CDP) 160 mg/m2. The chemotherapy
course was repeated in the sixth and eleventh week with 2-
week intervals. During the 16th week, the patients were
submitted to surgery and chemotherapy was reinitiated on
the 10th post-operative day, following a protocol identical
to the pre-operative one with the single difference that on
the 21st day, after administration of adriamycin, ifofosfa-
mide (IFO) 10 g/m2 was initiated. In patients over 40 years,
methotrexate was not used and was replaced by adriamycim
75 mg/m2. Three identical therapeutic cycles were
completed, after which the patient was re-evaluated from
a clinical, laboratorial and radiological stand point.
2.3. Surgery
All operations were performed through a lateral thoracot-
omy, but bilateral metastases were removed through a
median sternotomy in one patient. Thorough palpation of
the lung was carried out to detect metastases not identi®ed
by the chest X-ray or CT scan. Palpable abnormalities that
did not appear to be obvious granulomas were excised by
wedge resection, segmental resection of formal pulmonary
resection, and were subjected to thoracotomy for removal of
these lesions. Resection of the metastases was as conserva-
tive of the lung parenchyma as possible. Enucleations or
wedge resections were performed in the majority of the
cases. When this was not possible, a lobectomy was
performed. The mean time interval between the resection
of the primary tumour and the occurrence of pulmonary
metastases was 22 months (range 4±122 months). Table 1
indicates the localisation of metastases. In four patients
there was bilateral involvement. In one of these the metas-
tases were removed through a median sternotomy and in the
other three through sequential thoracotomies. Resected
metastases were sent for histologic study. The degree of
necrosis was evaluated from seriated sections. At the end,
the mean necrotic volume was calculated.
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Fig. 1. Chemotherapy protocol utilised pre and postoperatively in 31
patients subjected to surgical excision of pulmonary metastases of osteo-
genic sarcoma of the limbs (see explanation in the text).
Table 1




Inferior lobe 31 (1n)a
Left lung
Superior lobe 31
Inferior lobe 32 (1n)a
a In two patients who had lobectomies, the total number of metastases in
the resected lobes is unknown.
3. Results
In this group of 31 patients, 45 thoracotomies were
performed. Eight patients required more than one thoracot-
omy, four required two thoracotomies, two required three
thoracotomies and two required four thoracotomies. In these
cases, the interval between surgeries was lower than that
between resection of the primary tumour and ®rst thoracot-
omy (22 months): 9.2 months (range 2±14 months) between
®rst and second thoracotomies and 14.8 months (6±24
months) between second and subsequent thoracotomies.
Enucleations or wedge resections were performed on 40
occasions and ®ve patients had lobectomies.
The mean number of metastases diagnosed by CT scan
was 3.2 (range 1±8). The mean number of metastases
resected in each surgery was 3.4 (range 1±10). Only metas-
tases ,1 cm in size accounted for the discrepancy. In
patients subjected to more than one thoracotomy the mean
number of metastases resected was 5.7 (2±10). The extent of
necrosis varied between 60 and 95% but in all patients
subjected to more than one thoracotomy, pathological
examination showed an extent of necrosis of the metastases
lower than 80%, as observed by seriated sections in the
histologic study.
There was no operative mortality or major morbidity, but
one patient required ventilation for 48 h.
All patients were followed for a mean period of 28
months (range 6±72 months) after the ®rst thoracotomy.
Ten patients (32.2%) died of related causes, at a mean of
19.4 months after thoracic surgery (6±30 months) and 8±130
months after treatment of the primary tumour. All but one
died of uncontrollable pulmonary metastisation. Three of
the 10 had more than one thoracotomy.
The 3-year survival was 61% for the patients with
pulmonary metastases. By comparison, a 3-year survival
of 79% was recorded for patients with osteosarcoma without
metastases treated at our institution during the same period
of time. Five of the eight patients with more than one thor-
acotomy (62%) are alive. There did not appear to be a
correlation between survival and the number and localisa-
tion of the metastases. All patients with metastases not
resected died.
4. Discussion
It is thought that 40±60% of all primary sarcomas of the
limbs treated surgically develop pulmonary metastases
within 3 years. If not resected, the mean survival of patients
is around 6 months [15]. Because the dissemination of
osteogenic sarcoma is through the haematogenous route,
the tumour cells are trapped in the pulmonary capillary
bed. Hence the lungs are, by far, the most frequent location
for distant metastases in these tumours.
The ®rst intentional resection of a pulmonary metastasis,
secondary to a renal tumour, was performed in 1939 by
Barney and Churchill [8]. Other surgeons followed this
example and in 1947 Alexander and Haight [9] found that
24 patients had been operated on for resection of pulmonary
metastases. However, this surgery was then performed only
in very selected patients, all having a single pulmonary
metastasis and with a recurrence-free interval of at least 2
years.
Martini et al. [6] and Morton et al. [10] compared the
survival of patients with unilateral and bilateral pulmonary
resection and concluded that the survival was identical.
Thereafter, the surgical attitude towards resection of
pulmonary metastases has been more aggressive, especially
after the studies of Morrow et al. [11] demonstrated almost
identical survival for patients with a single metastasis and
those with multiple metastases (27% and 22% survival,
respectively).
Surgery for resection of pulmonary metastases is usually
simple and carries low mortality risk, even when multiple
lesions are present, provided that the amount of pulmonary
parenchyma removed does not signi®cantly compromise
global pulmonary function. Resection must be as conserva-
tive for parenchyma as possible and patients with sarcoma
of the limbs are usually young and have a normal respiratory
function. We did not have mortality in this series and there
were no signi®cant respiratory complications.
Carter et al. [12] found, as did we in this series, that
patients who had resection of pulmonary metastases had a
better prognosis than those who, for any reason, had not. But
they did not ®nd a signi®cant relationship between survival
and the number and bilaterality of metastases. However,
these authors found that patients with metastases localised
to a single lobe had a longer survival than patients with
metastases in more than one lobe.
On the other hand, Girard et al. [13] found that in patients
with resectable pulmonary metastases from sarcoma and
carcinoma, the number of metastases had little in¯uence
in the surgical decision. They advised delaying the decision
to thoracotomy in patients with several metastases until a
signi®cant interval has shown that metastatic disease
remains resectable and con®ned to lungs.
Resection of pulmonary metastases results in 50±70% 3-
year survival and 30±50% 5-year survival. Patients with
solitary metastases should have the best prognosis.
However, several authors were able to obtain similar results
in patients with several and bilateral lesions [14±15]. But the
long-term prognosis is dependent on the ability to achieve
complete surgical resection of pulmonary metastases.
Goorin et al. [16] found that 82% of patients who could
be made free of disease were long-term survivors, as
compared to 13% of those who could not. But even with
an aggressive surgical approach to the pulmonary lesion,
only 42% of their patients could be made free of disease.
A signi®cant number of patients in our series required
additional thoracotomies for resection of metastases not
present or not detected during the initial thoracotomy.
This did not appear to affect survival negatively. However,
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the time between 1st and 2nd thoracotomies and between
2nd and subsequent thoracotomies was signi®cantly shorter
than that between the operation for removal of the primary
tumour and the ®rst thoracotomy. Beattie et al. [17] reported
survival of up to 22 years after multiple resection of
pulmonary metastases. In their series of 22 patients treated
surgically, before the chemotherapy era, there were six 10-
year, ®ve 15-year and four 19-year survivors. But of concern
was the ®nding that 50% of the 10-year survivors developed
second primary malignant tumours during their second
decade of follow-up.
We could not ®nd a correlation between length of survi-
val and the number, localisation and bilaterality of metas-
tases but there appeared to be a direct relationship with the
degree of necrosis of the metastases. However, Inoue et al.
[18] found the disease-free interval to be a signi®cant prog-
nostic factor in a series of 22 patients subjected to 34 thor-
acotomies during a 15-year period. Repeated thoracotomy
for removal of additional metastases is, therefore, bene®cial,
which justi®es close follow-up of the patients, with frequent
diagnostic imaging.
Based on the fact that occult contralateral metastases are
present in 20% of the cases, Pastorino et al. [15] used
median sternotomy routinely for the treatment of lung
metastases. In their experience with 68 patients treated
during a 4-year period, about one third of the patients clini-
cally with unilateral lesions were found to have contralateral
lesions that were resected through the median sternotomy.
Nonetheless, they observed relapses in 21 patients, mostly
within 6 months from the sternotomy.
Chemotherapy has been used as an adjuvant or neoadju-
vant therapy in the treatment of both primary and metastatic
malignant tumours. Markedly improved survival rates have
been reported [19]. Chemotherapy aims at destruction of
residual malignant cells after surgical excision of the
tumour or metastases. Besides, preoperative chemotherapy
improves the resectability rate of pulmonary metastases,
which was 86% in the experience of Eilber et al. [20], as
compared to only 45% in patients who did not receive
chemotherapy.
Chemotherapy is utilised in the form of multi-drug proto-
cols administrated both pre and post surgery. Bacci et al.
[21] have demonstrated improved results in patients who
had metastatic disease at the time of the initial diagnosis
and who underwent simultaneous resection of the primary
tumour and of the pulmonary metastases. In these authors'
experience, some of the metastases completely disappeared
after chemotherapy. Marina et al. [22] also found improved
outcomes in patients with metastatic pulmonary disease at
the time of the initial diagnosis in the new era of multi-agent
drug therapy, when compared with patients treated earlier
with single-agent or two-agent therapy. But it is important to
note that a much more aggressive surgical approach to the
lung metastases was also used in the patients treated in the
most recent period.
However, the majority of authors have used chemother-
apy as adjuvant therapy in association with surgery for
resection of metastases that have appeared later after
surgery to the primary tumours, with additional bene®ts
over those obtained with excision of metastases alone. In
our series, patients who had pulmonary metastases resected
surgically in association with chemotherapy had a lower
medium-term survival than those who did not have pulmon-
ary metastases. Nonetheless, the 3-year survival of 61% is
clearly an improvement over that commonly observed in
patients without either form of therapy.
In conclusion, aggressive surgery for removal of pulmon-
ary metastases associated with multi-agent chemotherapy
signi®cantly improves survival of patients with osteogenic
sarcoma of the limbs. Repeated thoracotomy, if further
metastases appear, is compatible with long-term survival.
Hence, close follow-up for early diagnosis of relapses is
essential in these patients.
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Appendix A. Conference discussion
Dr Grodzki (Szczecin, Poland): I would like to discuss one of your
selection criteria, because I think that excluding patients with metastases
to other organs, despite lungs, is not justi®ed, and other centers try to treat
them surgically with good results.
Dr Antunes: Well, I apologize, I may have not expressed myself
correctly. I excluded these from this study. They were not excluded from
surgical treatment, when that was felt appropriate.
Dr Athanassiadi (Athens, Greece): If I understood correctly, your surgi-
cal approach of choice is thoracotomy. I wonder why not a median ster-
notomy. Pulmonary metastases after osteosarcoma can be missed on a CT
scan, especially when their diameters are smaller than 1 cm. Through a
median sternotomy you have always the opportunity to inspect the other
lung.
Dr Antunes: Yes, you're quite right and I agree with you. A median
sternotomy is a very good mode of access for bilateral lesions. In our
circumstances, though, of the four patients who had bilateral involvement,
three of them had bilateral involvement treated sequentially rather than
synchronously. And in the one who had metastases on X-ray or CT scan
(we do both at one time) we did a median sternotomy, but we didn't ®nd
more in this instance. I think you're correct.
Dr Lerut (Leuven, Belgium): If you evaluate your patients after three
cycles and you see that they respond, do you continue your chemotherapy
until completed and subsequently go for surgery, or do you perform surgery
systematically after the three cycles? And if they respond, do you perform
chemotherapy after the surgery as well, after resection?
Dr Antunes: Yes, we will give chemotherapy after the surgery irrespec-
tive of what the results are and what the preoperative status was. But I may
not be entirely sure about all this, because, obviously, the excision of the
primary tumour is done in another department, and the chemotherapy is
done by yet another different department, so I'm not entirely sure of
whether all the patients who came to us were in fact the ones that did not
respond completely. That is, I'm not sure if there were patients who
responded completely and the metastases disappeared and, therefore,
were not referred to surgery. As you know very well, there are cases like
that, described in the literature, of complete remission of metastases after
chemotherapy. This is just the cohort of the patients who had thoracotomies
for resection of metastases.
Dr End (Vienna, Austria): You mentioned that postoperative morbidity
is very low, of course.
Dr Antunes: These were young patients.
Dr End: Could you comment on your complications in detail, if there
are any?
Dr Antunes: There was only one patient who had prolonged ventilation.
None of the other 30 patients required ventilation in the ward. They were
extubated on the table. But one patient who had a previous resection already
and probably was marginal in his lung function, because he had one lobect-
omy done previously, now followed by another lobectomy, required venti-
lation for a little bit more than 24 h.
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